>
Switch to:

OncoCyte EV-to-EBIT

: -6.82 (As of Today)
View and export this data going back to 2015. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, OncoCyte's Enterprise Value is $274.11 Mil. OncoCyte's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 was $-40.17 Mil. Therefore, OncoCyte's EV-to-EBIT for today is -6.82.

The historical rank and industry rank for OncoCyte's EV-to-EBIT or its related term are showing as below:

NAS:OCX' s EV-to-EBIT Range Over the Past 10 Years
Min: -12.46   Med: -6.8   Max: -2.35
Current: -6.81

-12.46
-2.35

During the past 8 years, the highest EV-to-EBIT of OncoCyte was -2.35. The lowest was -12.46. And the median was -6.80.

NAS:OCX's EV-to-EBIT is ranked lower than
99.99% of the 37 Companies
in the Biotechnology industry.

( Industry Median: 21.16 vs. NAS:OCX: -6.81 )

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. OncoCyte's Enterprise Value for the quarter that ended in Jun. 2021 was $477.56 Mil. OncoCyte's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 was $-40.17 Mil. OncoCyte's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2021 was -8.41%.


OncoCyte EV-to-EBIT Historical Data

The historical data trend for OncoCyte's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only -17.12 -7.33 -3.25 -5.03 -4.92

OncoCyte Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.88 -2.64 -4.92 -11.09 -11.89

Competitive Comparison

For the Biotechnology subindustry, OncoCyte's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

OncoCyte EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, OncoCyte's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where OncoCyte's EV-to-EBIT falls into.



OncoCyte EV-to-EBIT Calculation

OncoCyte's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=274.110/-40.174
=-6.82

OncoCyte's current Enterprise Value is $274.11 Mil.
OncoCyte's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-40.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoCyte  (NAS:OCX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

OncoCyte's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2021 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2021 ) =EBIT / Enterprise Value (Q: Jun. 2021 )
=-40.174/477.55584
=-8.41 %

OncoCyte's Enterprise Value for the quarter that ended in Jun. 2021 was $477.56 Mil.
OncoCyte's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-40.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoCyte EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of OncoCyte's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoCyte Business Description

OncoCyte logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, the company also developing screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through United States and it earns revenue from the sale of diagnostic tests.
Executives
Carter Jennifer L. director C/O DFP SPONSOR LLC 780 THIRD AVENUE, 37TH FLOOR NEW YORK NY 10017
Kalajian Tony T officer: Sr.VP/Chief Accounting Officer 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Parker Albert P officer: Chief Operating Officer C/O ONCOCYTE CORPORATION 1010 ATLANTIC AVENUE, SUITE 102 ALAMEDA CA 94501
Levine Mitchell S officer: Chief Financial Officer ONE FERRY BUILDING, SUITE 255 SAN FRANCISCO CA 94111
Andrews Ronald Asbury director, officer: Chief Executive Officer 5791 VAN ALLEN WAY CARLSBAD CA 92008
Redmond Cavan M. director 5 GIRALDA FARMS MADISON NJ 07940
Griffith Melinda director 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Arno Andrew director C/O MERRIMAN CURHAN FORD GROUP, INC. 600 CALIFORNIA STREET, 9TH FLOOR SAN FRANCISCO CA 94108
Kingsley Alfred D director 150 E 57TH STREET NEW YORK NY 10022
Last Andrew J. director 3420 CENTRAL EXPRESSWAY SANTA CLARA CA 95051
Broadwood Capital Inc 10 percent owner 724 FIFTH AVENUE 9TH FLOOR NEW YORK NY 10019
Broadwood Partners, L.p. 10 percent owner BROADWOOD CAPITAL INC. 724 FIFTH AVENUE, 9TH FLOOR NEW YORK NY 10019
Bradsher Neal C 10 percent owner PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: BRADSHER NEAL C a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Ross Douglas T. officer: Chief Medical Officer 15 CUSHING IRVINE CA 92618
Sundar Padma officer: SVP, Marketing & Market Access 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501

OncoCyte Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)